- Pfizer's Q1 2025 revenue dipped 6% due to reduced Paxlovid sales and shifts in Medicare.
- The company aims for significant cost reductions, targeting $4.5 billion savings by 2025.
- Analyst forecasts suggest a potential upside of nearly 20% for Pfizer's stock price.
Pfizer Inc. (PFE, Financial) recently announced its first-quarter 2025 financial results, reporting a revenue of $13.7 billion. This marks a 6% decline, primarily driven by the decreasing sales of Paxlovid and changes in Medicare policies. Despite these challenges, the company remains resilient, underscoring its strategic focus on research and development. In line with this commitment, Pfizer has decided to discontinue the development of danuglipron. Furthermore, the company is aggressively pursuing cost-cutting strategies, with an ambitious goal to save $4.5 billion by 2025. For the full year, Pfizer maintains its revenue guidance between $61 billion and $64 billion, with an expected earnings per share (EPS) ranging from $2.80 to $3.00.
Wall Street Analysts Forecast
In terms of market predictions, 19 analysts have provided their one-year price targets for Pfizer Inc. (PFE, Financial). The average target price is $28.71, with a high projection of $41.43 and a low estimate of $22.00. This average target implies a potential upside of 19.91% from the current stock price of $23.94. For a deeper insight into these projections, visit the Pfizer Inc (PFE) Forecast page.
Addressing the brokerage firms' consensus, Pfizer Inc. (PFE, Financial) has been assigned an average recommendation rating of 2.6, which corresponds to a "Hold" status. The rating scale utilized ranges from 1 to 5, where 1 indicates a Strong Buy and 5 represents a Sell.
According to GuruFocus estimates, Pfizer Inc.'s (PFE, Financial) GF Value projected for the next year is $28.58, suggesting an upside of 19.38% from the current price level of $23.94. The GF Value is a proprietary metric by GuruFocus that represents the fair trading value of a stock, calculated by considering the stock's historical trading multiples and the company's past growth alongside future performance forecasts. More comprehensive data is available on the Pfizer Inc (PFE) Summary page.